All eyes have been on the pharma industry throughout the pandemic. As a result, there has been a focus on the need for strategic medical affairs teams. The capabilities of every medical affairs team include evidence generation and evidence dissemination.

The team must bring insights from all avenues of the healthcare system: research and development, commercial, patients, physicians, and even payers. The insights generated from these systems will then form the basis of the entire medical strategy of the pharmaceutical company. 

Because the medical affairs team is also able to evaluate and analyze the data gathered, the team acts as a bridge between the clinical development teams and commercial/market access teams. This enables us to ensure that valued knowledge determines the shape of clinical decision-making in patient care.

The leaders of the industry use the insights provided by medical affairs to build and utilize an integrated plan for the successful launch and usage of a product.  An efficient integration of all insights from all teams requires consistent discussion and debate, and dialogue between the teams. The industry can look to Reuters Pharma to facilitate this annual conversation. 

Reuters Pharma

Reuters Pharma provides a hub for the exchange of ideas between the leaders in the industry.  During the Reuters Event, there will be an industry-focused conversation on key topics leading pharma in 2022. This event is held to provide content that is driven by experts in their fields: marketing, commercial, data & analytics, patient engagement, patient advocacy, medical affairs, market access, RWE and clinical.

The goals of this conversation are so that the “strongest ideas and insights are brought to the fore in a transparent, trustworthy manner.” This year, the Reuters Events: Pharma USA 2022 event will be hosted at the Pennsylvania Convention Center in Philadelphia. Directors and managers from the Top 50 pharma companies and more will attend #REpharmaUSA. The speakers will highlight the current needs and the future of the industry. 

Reuters Events Pharma lists the 2022 industry defining themes to include:

• Data-driven transformation: Develop insights-led business models that deliver value for customers to drive improved outcomes.

• CX-evolved: Build customer experiences that will increase stakeholder trust and build brand loyalty. 

• Own access. Ensure equity: Ensure medical innovation thrives not dies; end financial toxicity, overcome systemic affordability issues, and remove health inequities.

• Champion healthcare’s most powerful stakeholder: Create a patient-driven culture to deliver scientific information that is accessible and trustworthy to diverse community needs. 

The agenda is driven by insights and co-created with more than 150 industry leaders. Reuters has partnered with the industry leader in medical affairs and medical science liaison (MSL) training and certifications, the Accreditation Council for Medical Affairs (ACMA).  The ACMA has established the benchmark for success for over 7,000+ professionals in the industry.

Many Board Certified Medical Affairs Specialists will be attending and speaking at Reuters Pharma USA 2022, demonstrating the standard of excellence within the field across the industry. Join Jill Massey, PharmD, MBA, BCMAS, Vice President Medical Affairs, Safety and Pharmacovigilance, Gilead Sciences as she discusses Medical Affairs Capabilities in 2032 for the ACMA. The combined efforts of the ACMA and Reuters Pharma ensure attendees gain actionable learnings that will genuinely encourage success and strategy.

Collaboration between healthcare leaders, internal, and external stakeholders is vital to leverage the power of education to improve patient outcomes. As a Gold Sponsor and media partner, the #REpharmaUSA event is able to offer continuing medical education/continuing education (CME/CE) credits to attendees ~ Register for Reuters!